Statin-associated adverse events

Wei Cheng Yuet, Htet Khine, Zahid Ahmad

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Although statins are well tolerated, their widespread use has raised awareness of rare adverse events. For example, the United States Food and Drug Administration (FDA) has issued product label warnings about statin-associated myopathy, incident diabetes, and cognitive impairment. Addi-tional statin-associated adverse effects include proteinuria, transaminitis, and hemorrhagic stroke. The underlying pathophysiology of these adverse events remains unclear, and thus little guidance exists on addressing these issues at the bedside. Although statin-associated myopathy is common, many patients eventually tolerate a statin – albeit at less than ideal doses. Incident diabetes remains difficult to predict, but high statin potency, increasing age, and pre-existing diabetes risk factors may predispose patients. Cognitive impairment – described mostly in case reports – may resolve after discontinuation of the offending statin. Rosuvastatin is linked to dose-dependent proteinuria. Elevated transaminases are reversible and unlikely to cause severe consequences. History of cerebrovascular disease increases the risk of hemorrhagic stroke on statin therapy. Overall, a thorough understanding of statin-associated adverse events will help health care providers manage patients who develop these complications. Here, we review the evidence for several statin-associated adverse effects and the implications for clinical practice.

Original languageEnglish
Pages (from-to)17-24
Number of pages8
JournalClinical Medicine Insights: Therapeutics
Volume7
DOIs
StatePublished - 7 Jul 2015

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Muscular Diseases
Proteinuria
Stroke
Cerebrovascular Disorders
United States Food and Drug Administration
Transaminases
Health Personnel

Keywords

  • Cognitive impairment
  • Diabetes risk
  • HMG-CoA reductase inhibitor
  • Myopathy
  • Statin

Cite this

Yuet, Wei Cheng ; Khine, Htet ; Ahmad, Zahid. / Statin-associated adverse events. In: Clinical Medicine Insights: Therapeutics. 2015 ; Vol. 7. pp. 17-24.
@article{a579e6030a8f4ad9b992af0ca751ba4d,
title = "Statin-associated adverse events",
abstract = "Although statins are well tolerated, their widespread use has raised awareness of rare adverse events. For example, the United States Food and Drug Administration (FDA) has issued product label warnings about statin-associated myopathy, incident diabetes, and cognitive impairment. Addi-tional statin-associated adverse effects include proteinuria, transaminitis, and hemorrhagic stroke. The underlying pathophysiology of these adverse events remains unclear, and thus little guidance exists on addressing these issues at the bedside. Although statin-associated myopathy is common, many patients eventually tolerate a statin – albeit at less than ideal doses. Incident diabetes remains difficult to predict, but high statin potency, increasing age, and pre-existing diabetes risk factors may predispose patients. Cognitive impairment – described mostly in case reports – may resolve after discontinuation of the offending statin. Rosuvastatin is linked to dose-dependent proteinuria. Elevated transaminases are reversible and unlikely to cause severe consequences. History of cerebrovascular disease increases the risk of hemorrhagic stroke on statin therapy. Overall, a thorough understanding of statin-associated adverse events will help health care providers manage patients who develop these complications. Here, we review the evidence for several statin-associated adverse effects and the implications for clinical practice.",
keywords = "Cognitive impairment, Diabetes risk, HMG-CoA reductase inhibitor, Myopathy, Statin",
author = "Yuet, {Wei Cheng} and Htet Khine and Zahid Ahmad",
year = "2015",
month = "7",
day = "7",
doi = "10.4137/CMT.S18865",
language = "English",
volume = "7",
pages = "17--24",
journal = "Clinical Medicine Insights: Therapeutics",
issn = "1179-559X",
publisher = "Libertas Academica Ltd.",

}

Statin-associated adverse events. / Yuet, Wei Cheng; Khine, Htet; Ahmad, Zahid.

In: Clinical Medicine Insights: Therapeutics, Vol. 7, 07.07.2015, p. 17-24.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Statin-associated adverse events

AU - Yuet, Wei Cheng

AU - Khine, Htet

AU - Ahmad, Zahid

PY - 2015/7/7

Y1 - 2015/7/7

N2 - Although statins are well tolerated, their widespread use has raised awareness of rare adverse events. For example, the United States Food and Drug Administration (FDA) has issued product label warnings about statin-associated myopathy, incident diabetes, and cognitive impairment. Addi-tional statin-associated adverse effects include proteinuria, transaminitis, and hemorrhagic stroke. The underlying pathophysiology of these adverse events remains unclear, and thus little guidance exists on addressing these issues at the bedside. Although statin-associated myopathy is common, many patients eventually tolerate a statin – albeit at less than ideal doses. Incident diabetes remains difficult to predict, but high statin potency, increasing age, and pre-existing diabetes risk factors may predispose patients. Cognitive impairment – described mostly in case reports – may resolve after discontinuation of the offending statin. Rosuvastatin is linked to dose-dependent proteinuria. Elevated transaminases are reversible and unlikely to cause severe consequences. History of cerebrovascular disease increases the risk of hemorrhagic stroke on statin therapy. Overall, a thorough understanding of statin-associated adverse events will help health care providers manage patients who develop these complications. Here, we review the evidence for several statin-associated adverse effects and the implications for clinical practice.

AB - Although statins are well tolerated, their widespread use has raised awareness of rare adverse events. For example, the United States Food and Drug Administration (FDA) has issued product label warnings about statin-associated myopathy, incident diabetes, and cognitive impairment. Addi-tional statin-associated adverse effects include proteinuria, transaminitis, and hemorrhagic stroke. The underlying pathophysiology of these adverse events remains unclear, and thus little guidance exists on addressing these issues at the bedside. Although statin-associated myopathy is common, many patients eventually tolerate a statin – albeit at less than ideal doses. Incident diabetes remains difficult to predict, but high statin potency, increasing age, and pre-existing diabetes risk factors may predispose patients. Cognitive impairment – described mostly in case reports – may resolve after discontinuation of the offending statin. Rosuvastatin is linked to dose-dependent proteinuria. Elevated transaminases are reversible and unlikely to cause severe consequences. History of cerebrovascular disease increases the risk of hemorrhagic stroke on statin therapy. Overall, a thorough understanding of statin-associated adverse events will help health care providers manage patients who develop these complications. Here, we review the evidence for several statin-associated adverse effects and the implications for clinical practice.

KW - Cognitive impairment

KW - Diabetes risk

KW - HMG-CoA reductase inhibitor

KW - Myopathy

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=84940190945&partnerID=8YFLogxK

U2 - 10.4137/CMT.S18865

DO - 10.4137/CMT.S18865

M3 - Review article

AN - SCOPUS:84940190945

VL - 7

SP - 17

EP - 24

JO - Clinical Medicine Insights: Therapeutics

JF - Clinical Medicine Insights: Therapeutics

SN - 1179-559X

ER -